Clinical trial
Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk…
NCT00450307 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00450307 |
|---|---|
| Title | Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed Neuroblastoma |
| Official title | 3F8 Antibody Dose Escalation Plus Granulocyte-Macrophage Colony-Stimulating Factor in High-Risk Neuroblastoma: A Phase I Trial |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neuroblastoma |
| Intervention type | Biological |
| Interventions | monoclonal antibody 3F8, sargramostim |
| Enrollment | 32 |
| Start date | Jun 1, 2005 |
| Primary completion | Apr 1, 2013 |
| Completion | Apr 1, 2013 |
| First posted | Mar 22, 2007 |
| Last update posted | Oct 16, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: